Vixotrigine
Vixotrigine is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
21 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neuralgia | D009437 | EFO_0009430 | — | 6 | 4 | 2 | — | — | 12 |
| Trigeminal neuralgia | D014277 | EFO_1001219 | G50.0 | 3 | 1 | 2 | — | — | 6 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Radiculopathy | D011843 | — | M54.1 | — | 3 | — | — | — | 3 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | 1 | — | — | — | 1 |
| Small fiber neuropathy | D000071075 | — | — | — | 1 | — | — | — | 1 |
| Erythromelalgia | D004916 | — | I73.81 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 4 | — | — | — | — | 4 |
| Drug interactions | D004347 | — | — | 2 | — | — | — | — | 2 |
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | 2 | — | — | — | — | 2 |
| Diabetic neuropathies | D003929 | EFO_1000783 | — | 1 | — | — | — | — | 1 |
| Polyneuropathies | D011115 | EFO_0009562 | A69.22 | 1 | — | — | — | — | 1 |
| Hyperalgesia | D006930 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Vixotrigine |
| INN | vixotrigine |
| Description | Vixotrigine (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name), formerly known as raxatrigine (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name), is an analgesic which is under development by Convergence Pharmaceuticals for the treatment of lumbosacral radiculopathy (sciatica) and trigeminal neuralgia (TGN). Vixotrigine was originally claimed to be a selective central Nav1.3 blocker, but was subsequently redefined as a selective peripheral Nav1.7 blocker. Following this, vixotrigine was redefined once again, as a non-selective voltage-gated sodium channel blocker. As of January 2018, it is in phase III clinical trials for trigeminal neuralgia and is in phase II clinical studies for erythromelalgia and neuropathic pain. It was previously under investigation for the treatment of bipolar disorder, but development for this indication was discontinued.
|
| Classification | Small molecule |
| Drug class | sodium channel blockers, signal transduction modulators |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | NC(=O)[C@@H]1CC[C@H](c2ccc(OCc3ccccc3F)cc2)N1 |
Identifiers
| PDB | — |
| CAS-ID | 934240-30-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3544913 |
| ChEBI ID | — |
| PubChem CID | 16046068 |
| DrugBank | — |
| UNII ID | QQS4J85K6Y (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 189 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use